| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4923 | St-2001 | Novel potent A 1 R/A 2A R/H 3 R multitargeting ligand (MTL) |
|
| DCC4924 | St-2262 | Novel selective NaV1.7 inhibitor, blocking the extracellular vestibule of the channel with an IC50 of 72 nM and greater than 200-fold selectivity over off-target sodium channel isoforms, NaV1.1-1.6 and NaV1.8 |
|
| DCC4925 | St4070 | Highly selective FAAH>fatty acid amide hydrolase (FAAH) inhibitor |
|
| DCC4926 | St7710aa1 | Novel PARP-1 inhibitor, showing significant in vitro target inhibition and capability to substantially bypass the multidrug resistance mediated by Pgp |
|
| DCC4927 | Sta-9584 | Novel tubulin-binding vascular disrupting agent (VDA) |
|
| DCC4928 | Stad-2 | Cell permeable AKAP disruptor, selectively binding to PKA-RII and blocking the interaction of PKA-RI with AKAP |
|
| DCC4929 | Stalobacin I | Novel Lipopeptide Antibiotic with Potent Antibacterial Activity against Multidrug-Resistant Bacteria |
|
| DCC4930 | Stanozolol [10418-03-8] | Anabolic-androgenic steroid (AAS), acting as an agonist of the androgen receptor (AR) |
|
| DCC4931 | Stat3 -in-11 | Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
| DCC4932 | stat3 Inhibitor 6 | Novel inhibitor of STAT3 signaling pathway |
|
| DCC4933 | Stat3-in-13r | Novel inhibitor of STAT3, targeting SH2 domain |
|
| DCC4934 | Stat3-in-3 | Novel potent and selective inhibitor of STAT3 |
|
| DCC4935 | Stat3-in-a69 | Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
| DCC4936 | Stat3-in-b9 | Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145 |
|
| DCC4937 | Stat5a-in-27 | Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t |
|
| DCC4938 | Stat5b-in-6a | Highly Potent and Selective Inhibitor of the Transcription Factor STAT5b |
|
| DCC4939 | Stemazole | Novel human stem/progenitor cells proliferation activator, promoting survival and preserving stemness in human embryonic stem cells |
|
| DCC4940 | Sterigmatocystin | Natural inducer of G1 arrest in primary human esophageal epithelial cells but G2 arrest in immortalized cells |
|
| DCC4941 | Stf-038533 | Novel inhibitor of expression from canonical CREB response element-containing promoters |
|
| DCC4942 | Stg -001 | Novel RBP4 antagonist for treatment of Stargardt disease |
|
| DCC4943 | Stictic Acid | Natural anti-feline infectious peritonitis virus (FIPV) agent, specifically targeting the 3CLpro of FIPV and inhibiting its replication |
|
| DCC4944 | Sting Agonist 11 | Novel non-nucleotide STING agonist, demonstrating antitumor activity when dosed intratumorally in a syngeneic mouse model |
|
| DCC4945 | Sting Inhibitor C-171 | Novel covalent antagonist of hsSTING |
|
| DCC4946 | Stk-15 | Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
| DCC4947 | Stk-22 | Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
| DCC4948 | Stk295900 | Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay |
|
| DCC4949 | Stk508411 | Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18) |
|
| DCC4950 | Stk630921 | Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA) |
|
| DCC4951 | Stk683963 | Novel activator of cellular ATG4B activity |
|
| DCC4952 | Stock1n-65837 | Potent natural modulator of human Toll-like receptor 7 (TLR7) |
|
